Atea Pharmaceuticals, Inc.
AVIR
Rank in Stocks
#13953
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company,... Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Share Price
$4.41
Last synced: 2026-11-09
Market Cap
$353.70M
Change (1 day)
2.32%
Change (1 year)
26.00%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Atea Pharmaceuticals, Inc. (AVIR)
Category
Healthcare
EPS for Atea Pharmaceuticals, Inc. (AVIR)
EPS as of June 2026 TTM: $-2.08
According to Atea Pharmaceuticals, Inc.'s latest financial reports, its current EPS (TTM) is $-2.08. At the end of 2025 the company had an EPS of $-1.94, an increase over its 2024 EPS of $-2.00.
EPS history for Atea Pharmaceuticals, Inc. from 2018 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-2.08 | 7.22% |
| 2025 | $-1.94 | -3.00% |
| 2024 | $-2.00 | 22.70% |
| 2023 | $-1.63 | 17.27% |
| 2022 | $-1.39 | -195.21% |
| 2021 | $1.46 | -1,223.08% |
| 2020 | $-0.13 | -18.75% |
| 2019 | $-0.16 | -82.22% |
| 2018 | $-0.90 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -852.88% |
US
|
|
| $-7.07 | 239.90% |
US
|
|
| $-5.29 | 154.33% |
AU
|
|
| $12.88 | -719.24% |
BE
|
|
| $21.56 | -1,136.54% |
NL
|
Questions about Atea Pharmaceuticals, Inc.'s earnings per share (EPS)
What is Atea Pharmaceuticals, Inc.'s earnings per share (EPS)?
Atea Pharmaceuticals, Inc.'s earnings per share (EPS) over the last twelve months is $-2.08, as of Jun 2026.
What was Atea Pharmaceuticals, Inc.'s earnings per share (EPS) in 2025?
In 2025, Atea Pharmaceuticals, Inc.'s earnings per share (EPS) was $-1.94, compared with $-2.00 in 2024.
How has Atea Pharmaceuticals, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Atea Pharmaceuticals, Inc.'s earnings per share (EPS) was highest in 2021 ($1.46) and lowest in 2024 ($-2.00).
How does Atea Pharmaceuticals, Inc.'s earnings per share (EPS) compare with similar companies?
Atea Pharmaceuticals, Inc.'s earnings per share (EPS) ($-2.08) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.